We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • eCFR and Guidances
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Webinar Recordings » Extractables and Leachables: 101 - Webinar Recording/Transcript

Other Options

Audio Recording/Transcript - April 12, 2018

$287.00

Audio Recording/Transcript - April 12, 2018

$258.00

Audio Recording/Transcript - April 12, 2018

$244.00

Audio Recording/Transcript - April 12, 2018

$230.00

Audio Recording/Transcript - April 12, 2018

$215.00

Extractables and Leachables: 101 - Webinar Recording/Transcript

$287.00
Webinar Recordings

Product Details

Extractables and Leachables: 101

Once confined to the fringes of FDA regulation, extractables and leachables are now in sharp focus.

Driven by ICH Q3D guideline compliance requirements, plus a substantial shift in metal impurity standards, the FDA now expects compliance in nearly all dosage forms; and scrutiny extends to materials such as manufacturing equipment and dosing devices.

But confusion and misinformation abound. Many sponsors still run into trouble understanding and performing appropriate E&L studies, leading to costly delays and raising the risk of regulatory sanctions.

Dr. Wayland Rushing, Director of Scientific Affairs at EAG Labs, is the expert to guide you through this regulatory thicket. Dr. Rushing sorts it all out:

  • Extractables and leachables: What they are, special issues they pose
  • Regulatory requirements: ICH Q3D guideline requirements and more
  • Designing an E&L program: What to consider
  • Analytical challenges associated with E&L
  • And much more!

Dr. Rushing’s 15-year career has focused on CMC development programs for a wide array of biopharmaceutical clients including parenterals, inhalation drugs and other pharmaceuticals with complex delivery systems. Let him help you get into full compliance.

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing